EU MDR Compliance: A Practical Guide

The EU Medical Device Regulation (MDR, 2017/745) represents the most significant overhaul of European medical device governance in 25 years. With the full transition now complete, manufacturers operating under legacy MDD certificates face immediate compliance obligations that many have underestimated in both scope and cost.

The three most impactful changes under EU MDR are: (1) a dramatically higher bar for clinical evidence, requiring clinical evaluation reports (CERs) backed by clinical investigation data rather than literature reviews alone for most Class IIb and III devices; (2) a mandatory Unique Device Identification (UDI) system requiring registration in EUDAMED; and (3) significantly enhanced Post-Market Surveillance (PMS) obligations, including Periodic Safety Update Reports (PSURs) for Class IIa and above.

In our experience working with medical device manufacturers, the most common gaps identified during MDR transition audits are: inadequate clinical evaluation methodology (particularly the failure to conduct SOTA - State of the Art - analysis), missing or outdated risk management files that do not reference EN ISO 14971:2019, and PMS systems that collect adverse event data but do not systematically feed it back into the Technical Documentation update cycle.

For manufacturers currently managing MDR compliance, we recommend a phased approach: start with a gap assessment against the MDR Annex I General Safety and Performance Requirements, prioritise Technical Documentation remediation for your highest-risk product lines, engage your Notified Body early for any device requiring CER review, and implement a living document management system that supports ongoing PMS obligations. With the right structure, full MDR compliance is achievable within 9–12 months for most Class IIa portfolios.